| 摘要 |
The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of an agent that suppresses the activity of endothelin. Such agents may take the form of: 1) an endothelin-converting enzyme (ECE) inhibitor such as phosphoramidon, or 2) an endothelin receptor antagonist such as bosentan, tezosentan, sitaxsentan, atrasentan, darusentan, clazosentan, or BQ-123. Respiratory disorders include emphysema, asthma, bronchitis, bronchiectasis, pneumonia, adult respiratory distress syndrome, neonatal respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, persistent pulmonary hypertension of the newborn, and neoplasia. The treatment is intended for a variety of mammals, such as premature neonates to adult humans.
|
